Novo Nordisk A/S, the Danish pharmaceutical company, has unveiled plans to invest €2.1 billion ($2.3 billion) to expand its production capacity in France. The investment aims to meet the growing demand for Novo's weight-loss medications, particularly the popular drugs Wegovy and Ozempic. Construction work has already commenced at Novo's facility in Chartres, southwest of Paris, which manufactures pre-filled injector pens for these medications, as well as insulin.
The weight-loss market is projected to reach $100 billion by the end of the decade, intensifying competition among pharmaceutical companies. Recognizing this opportunity, Novo Nordisk is racing to expand its factories and production lines to keep up with the rising demand for its sought-after weight-loss drugs.
The expansion in Chartres will more than double the size of Novo's site and is expected to create over 500 new jobs. President Emmanuel Macron visited the plant to congratulate Novo and its CEO, Lars Fruergaard Jorgensen, emphasizing the positive impact of foreign investment on France's economy and promoting his efforts to make France a more business-friendly country.
Novo's weight-loss medications, Ozempic and Wegovy, have gained significant attention, with endorsements from celebrities and entrepreneurs like Elon Musk. This attention has propelled Novo Nordisk to become Europe's most valuable company, leading to a 50% surge in its stock price this year.
Both Ozempic and Wegovy contain semaglutide, an active ingredient that mimics the action of a gut hormone, making patients feel full and aiding in weight loss. Wegovy, in particular, has shown promising results, helping users achieve an average weight loss of 15% and demonstrating cardiovascular benefits. However, Novo Nordisk has faced challenges meeting the high demand for these medications, resulting in shortages and difficulties for some diabetes patients.
To address this issue, Novo plans to invest over $6 billion to construct a massive manufacturing facility in Denmark. The recent investment in the French facility in Chartres further demonstrates the company's commitment to expanding production capabilities and ensuring a stable supply of these medications.
President Macron's industrial revival plans have facilitated Novo's expansion in France. Measures such as tax credits for investment and streamlining procedures for establishing new factories have attracted foreign companies like Novo Nordisk. Although it is unclear whether public subsidies are involved in this specific investment, President Macron's administration has been focused on supporting and revitalizing French industry.
Novo's investment in the Chartres facility follows an earlier announcement in January of a €130 million investment to expand the site's capacity. Currently, the Chartres facility employs over 1,500 people and produces insulin that benefits more than eight million patients worldwide.
With Novo Nordisk's ambitious expansion plans in France and Denmark, the company aims to meet the growing demand for its weight-loss medications and secure its position as a key player in the global pharmaceutical industry.